Day: March 21, 2023

Generation Bio to Participate in the BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines

Written by Customer Service on March 21, 2023. Posted in Public Companies.

CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) — Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will participate in the Novel LNPs Targeting Diverse Tissues panel at the BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines, which will take place virtually on Tuesday, March 28th at 10:00 a.m. ET. About Generation BioGeneration Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral genetic medicine platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing...

RadNet, Inc. to Present at the Sidoti & Company 2023 Virtual Spring Investor Conference on Wednesday, March 22nd

Written by Customer Service on March 21, 2023. Posted in Public Companies.

LOS ANGELES, March 21, 2023 (GLOBE NEWSWIRE) — RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the Sidoti & Company Spring 2023 Conference on Wednesday, March 22nd at 01:00 p.m. Eastern Time. There will be simultaneous and archived webcasts available at https://sidoti.zoom.us/webinar/register/WN_AOM-Ck3RRlaSQmMcOvecfA and www.radnet.com under the “About RadNet” menu section and “News and Press Releases” sub-menu of the website.Details for RadNet’s Presentation:Date: Wednesday, March 22, 2023Time: 01:00 p.m. Eastern TimeAbout RadNet, Inc. RadNet,...

Sonoco Raises First-Quarter 2023 Financial Guidance

Written by Customer Service on March 21, 2023. Posted in Public Companies.

HARTSVILLE, S.C., March 21, 2023 (GLOBE NEWSWIRE) — Sonoco Products Company (NYSE: SON), a diversified global packaging leader, today provided updated first-quarter 2023 earnings guidance and announced its earnings release date and investor conference call information. Sonoco Provides First-Quarter 2023 Financial Update Based on year-to-date results and an updated forecast for the remainder of the first quarter, Sonoco expects first-quarter 2023 base (adjusted) earnings to be in the range of $1.30 to $1.40 per diluted share, which is above the Company’s previously communicated guidance range of $1.15 to $1.25 per diluted share. (See base earnings definition later in this release.) Sonoco anticipates results to be better than previously expected due to improving productivity, lower than expected input costs, and higher demand than...

Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Written by Customer Service on March 21, 2023. Posted in Earnings Releases And Operating Results.

Received U.S. Food and Drug Administration (FDA) acceptance of Investigational New Drug (IND) application for CUE-102 in Wilms’ Tumor 1 (WT1)-expressing cancers and initiated dosing in a Phase 1 dose escalation monotherapy trial at 1mg/kg. Granted FDA Fast Track Designation for CUE-101 for the treatment of HPV+ recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) as a monotherapy and in combination with pembrolizumab (KEYTRUDA®). Presented new positive data from the ongoing Phase 1 trials of CUE-101 in combination with pembrolizumab and as a monotherapy for HPV+ (R/M HNSCC) at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting on November 10, 2022. Entered into securities purchase agreements with accredited investors for a $30 million private investment in public equity (PIPE) financing. The transaction...

ADDvantage Technologies Revenue Full-Year Increases 56% to $97.0 million, Improves Bottom line by $7.0 million

Written by Customer Service on March 21, 2023. Posted in Earnings Releases And Operating Results.

Telco Sales Increase 59%, Wireless Revenues Up 49%, for Year-Ended December 31, 2022 CARROLLTON, Texas, March 21, 2023 (GLOBE NEWSWIRE) — ADDvantage Technologies Group, Inc. (NASDAQ: AEY) (“ADDvantage Technologies” or the “Company”) today reported financial results for the three and 12 months ended December 31, 2022, the fourth quarter of 2022. The Company has changed its fiscal year end from September 30 to December 31 and the current fiscal year runs from January 1, 2022 through December 31, 2022 (fiscal 2022). “This was a milestone year for ADDvantage Technologies, as we grew both our segments and delivered full-year positive net income, even with a challenging fourth quarter impacted by weather and economic headwinds,” commented Joe Hart, Chief Executive Officer. “Our Telco segment drove the majority of our growth, and this...

Array Technologies, Inc. Reports Financial Results for the Fourth Quarter and Full Year 2022 – Delivers full year revenue increase of 92% from 2021 to $1.6 billion, exiting the year with Fourth Quarter 2022 gross margin of 20.0%

Written by Customer Service on March 21, 2023. Posted in Earnings Releases And Operating Results.

Fourth Quarter 2022 Financial HighlightsRevenue of $402.1 million Net loss to common stockholders of $17.3 million Adjusted EBITDA(1) of $51.7 million Basic and diluted net loss per share of $0.11 Adjusted diluted net income per share(1) of $0.10 Executed contracts and awarded orders at December 31, 2022 totaling $1.9 billionFull Year 2022 Financial HighlightsRevenue of $1,638 million Net loss to common stockholders of $43.6 million Adjusted EBITDA(1) of $128.7 million Basic and diluted net loss per share of $0.29 Adjusted diluted net income per share(1) of $0.38(1) A reconciliation of the GAAP to the most comparable Non-GAAP results is included below. ALBUQUERQUE, N.M., March 21, 2023 (GLOBE NEWSWIRE) — Array Technologies (NASDAQ: ARRY) (“Array” or “the Company”), a leading provider of tracker solutions, software and...

Evoke Pharma Reports Fourth Quarter and Full Year 2022 Financial Results

Written by Customer Service on March 21, 2023. Posted in Earnings Releases And Operating Results.

Fiscal year 2022 net product sales from prescriptions increased by 179% to $2.5 million versus 2021Patient enrollment increased by 149% compared with 2021 SOLANA BEACH, Calif., March 21, 2023 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its financial results for the fourth quarter and full year ended December 31, 2022, and recent corporate developments. “Evoke’s fiscal year 2022 was a period of tremendous growth and progress on several key fronts. Year-over-year revenues, new prescribers, prescription fills, and patient enrollments showed significant improvement in 2022 compared with 2021. In 2021, our prime achievement was to call attention to GIMOTI’s...

AAR reports third quarter fiscal year 2023 results

Written by Customer Service on March 21, 2023. Posted in Earnings Releases And Operating Results.

Third quarter sales of $521 million, up 15% over the prior year Third quarter GAAP diluted earnings per share from continuing operations of $0.62, compared to $0.63 in Q3 FY2022 Adjusted diluted earnings per share from continuing operations of $0.75, up 19% from $0.63 in Q3 FY2022 Third quarter cash flow provided by operating activities from continuing operations of $17 million Acquired Trax, a leading provider of aircraft MRO and fleet management softwareWOOD DALE, Ill., March 21, 2023 (GLOBE NEWSWIRE) — AAR CORP. (NYSE: AIR), a leading provider of aviation services to commercial and government operators, MROs, and OEMs, today reported third quarter fiscal year 2023 consolidated sales of $521.1 million and income from continuing operations of $21.8 million, or $0.62 per diluted share. For the third quarter of the prior year,...

Hyperfine, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results

Written by Customer Service on March 21, 2023. Posted in Earnings Releases And Operating Results.

GUILFORD, Conn., March 21, 2023 (GLOBE NEWSWIRE) — Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared portable MRI system™ today announced fourth quarter and full year 2022 financial results and provided a business update. “We made measurable progress at Hyperfine over the past year. We delivered $6.8 million in revenue in 2022, received multiple FDA clearances and international approvals, including CE Marking, in recent months, and saw a large number of publications and presentations on the clinical value of Swoop published and presented via major journals and meetings. We also implemented important measures to right size our business and extend our cash runway through the end of 2025, ending the year with a healthy balance sheet....

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results

Written by Customer Service on March 21, 2023. Posted in Earnings Releases And Operating Results.

REDWOOD CITY, Calif., March 21, 2023 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the fourth quarter and full-year ended December 31, 2022. Fourth Quarter 2022 and Recent Corporate HighlightsEnrollment is nearing completion in the randomized withdrawal period of Study C602, a long-term treatment study of DCCR (Diazoxide Choline) Extended-Release tablets for the treatment of Prader-Willi syndrome (PWS):58/63 (>90% of U.S. participants) have been randomized. 15/83 (18%) participants are in the U.K., where enrollment is expected to start imminently following recent approval of the protocol from the MHRA. 5 of 83 total participants...

Day: March 21, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice